Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

Study Background and Research Question

Herpes simplex virus 1 (HSV-1) is a ubiquitous human pathogen responsible for a spectrum of diseases, including recurrent cold sores, keratitis, and life-threatening encephalitis. Following acute lytic infection in mucosal epithelial cells, HSV-1 establishes lifelong latent infection in peripheral sensory and autonomic neurons. Reactivation from this latent state is clinically significant, yet the molecular mechanisms governing latency and reactivation remain incompletely understood, especially in human neurons, due to the limited accessibility of relevant human models. Most mechanistic studies have relied on animal systems, which do not fully recapitulate human neuronal biology or epigenetic regulation (paper). The central research question addressed by Oh et al. (2025) is: Can a robust, scalable in vitro human sensory neuron model be established from hiPSCs to recapitulate HSV-1 latency and reactivation, thereby enabling mechanistic analysis of neuron-intrinsic responses to HSV-1 infection (paper)?

Key Innovation from the Reference Study

The reference study by Oh et al. marks a pivotal advancement by establishing a protocol for rapidly differentiating human-inducible pluripotent stem cells (hiPSCs) into functionally mature sensory neurons. These neurons are electrically excitable and exhibit physiologically relevant ion channel expression. The authors then define experimental conditions under which HSV-1 can infect these neurons, enter latency, and be reactivated by canonical stimuli. Notably, the model demonstrates hallmarks of true viral latency: silenced lytic gene expression, robust latency-associated transcript (LAT) production, and deposition of heterochromatin marks on the viral genome (paper). This scalable, human-specific neuronal model overcomes major limitations of animal models, offering a platform to dissect human neuron-specific responses to HSV-1 and to test strategies for preventing viral reactivation or curtailing latent infection.

Methods and Experimental Design Insights

The methodological cornerstone of the study is the stepwise differentiation of hiPSCs into sensory neurons, building on protocols that drive fate commitment via defined morphogens and transcription factor modulation. The resulting neurons display:

• Excitability and mature action potentials, confirmed by electrophysiological recordings.
• Expression of sensory neuron markers and functional ion channels.

For HSV-1 infection studies, the authors infect differentiated neurons under conditions permissive for lytic or latent infection. Latency is assessed by:

• Absence of infectious virus in culture supernatants.
• Suppressed lytic gene expression (by qPCR and RNA-seq).
• Strong expression of LATs.
• Chromatin immunoprecipitation (ChIP) showing enrichment of histone modifications (H3K9me3, H3K27me3) associated with heterochromatin on viral promoters.

Reactivation is induced using forskolin and PI3K inhibitors, stimuli previously shown to trigger viral reactivation in other models.

Core Findings and Why They Matter

The study's principal findings include:

• hiPSC-derived sensory neurons can be efficiently infected by HSV-1 and support both lytic and latent infection states.
• Latently infected neurons exhibit no production of infectious virus, substantial reduction of lytic transcripts, and high levels of LAT expression—classic signatures of latency (paper).
• ChIP analyses reveal that latent HSV-1 genomes are packaged with heterochromatin marks, mirroring in vivo observations.
• Latency is reversible: established latent infection can be reactivated by forskolin or PI3K inhibition, demonstrating functional recapitulation of known neuronal triggers (paper).

This model thus provides a direct window into the neuron-intrinsic mechanisms of HSV-1 latency and reactivation in a human genetic background. It opens avenues for dissecting the interplay between host chromatin regulation and viral persistence, and for screening interventions aimed at blocking reactivation.

Protocol Parameters

• Assay: hiPSC differentiation to sensory neurons | Duration: ~2-3 weeks | Applicability: Human neuronal modeling | Rationale: Achieves physiologically relevant neuron phenotype for HSV-1 studies | source: paper
• Assay: HSV-1 infection (latent) | MOI: 0.1–1 | Applicability: Establishes latent infection in human sensory neurons | Rationale: Allows controlled comparison of lytic vs. latent infection | source: paper
• Assay: Reactivation stimulation | Agents: Forskolin, PI3K inhibitor | Applicability: Reactivates latent HSV-1 in vitro | Rationale: Validates model responsiveness to known triggers | source: paper
• Assay: Chromatin mark analysis | ChIP for H3K9me3/H3K27me3 | Applicability: Confirms epigenetic silencing of viral genome | Rationale: Benchmarks similarity to in vivo latency | source: paper

Comparison with Existing Internal Articles

While the reference study focuses on HSV-1 latency in human neurons, related research often explores the molecular regulation of neuronal fate and plasticity using pathway inhibitors. For example, LDN-193189, a potent and selective BMP type I receptor inhibitor, is widely employed for dissecting ALK2/ALK3-dependent signaling, modulating Smad1/5/8 phosphorylation, and protecting epithelial barrier integrity (internal article; internal article). These studies highlight the utility of BMP signaling pathway inhibitors for driving stem cell differentiation and controlling cellular responses to stress or injury, relevant for both developmental and disease modeling. Although BMP pathway modulation is not directly interrogated in the HSV-1 latency model, tools such as LDN-193189 remain crucial for optimizing differentiation of hiPSCs into defined lineages, including sensory neurons, and for evaluating the role of BMP signaling in neural plasticity (internal article).

Limitations and Transferability

Despite its significant advances, the model has limitations:

• In vitro hiPSC-derived neurons may lack the full spectrum of in vivo neuronal subtypes, supporting glia, or microenvironmental cues present in ganglia (paper).
• Latency and reactivation are studied over relatively short time frames; long-term stability and stochastic reactivation events remain to be fully validated.
• Some viral and host factors may be differentially regulated in vitro versus in vivo, potentially affecting generalizability.

Nevertheless, the system provides a tractable and renewable platform for genetic, pharmacological, and epigenetic analyses in a human context.

Why this cross-domain matters, maturity, and limitations

Bridging stem cell biology, neurovirology, and chromatin regulation, this model enables experimental questions previously restricted to non-human systems. However, translation of findings to clinical therapy will require additional validation in complex, multicellular, and in vivo contexts.

Research Support Resources

To advance studies of neuronal differentiation and pathway modulation, researchers commonly employ small molecule tools such as LDN-193189 (SKU A8324), a potent ALK2/ALK3 inhibitor for BMP pathway research. LDN-193189 is well-characterized for inhibiting Smad1/5/8 phosphorylation and has been used to control stem cell fate or preserve epithelial barrier function in both cell-based and animal models (source: internal article; product_spec). For protocols involving BMP signaling inhibition during neuronal differentiation or epithelial barrier studies, APExBIO's LDN-193189 provides a standardized, reproducible option. As always, ensure protocols align with current literature and workflow recommendations for concentration and timing.